Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04692103 · ClinicalTrials.gov registry record · Phase 2

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

A Phase 2 study of Stage IV Breast Cancer AJCC v6 and v7 and Estrogen Receptor Positive, sponsored by University of Washington.

Active
Registry status
Phase 2
Development phase
2
Enrollment target
1
Study location

NCT04692103 is a Phase 2 study of Stage IV Breast Cancer AJCC v6 and v7 and Estrogen Receptor Positive that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 2 participants, below the 137-participant average among 14 other Stage IV Breast Cancer AJCC v6 and v7 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04692103, a Phase 2 study of Stage IV Breast Cancer AJCC v6 and v7 and Estrogen Receptor Positive, is active but no longer recruiting, sponsored by University of Washington.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
2 participants
Enrollment target
1
Study location

Study Summary

This clinical trial studies use of F-18 16 alpha-fluoroestradiol (\[F-18\] FES) positron emission tomography (PET)/computed tomography (CT) in measuring tumor hormone receptor expression in patients undergoing endocrine-targeted therapy for newly diagnosed breast cancer or breast cancer that has come back or spread to other places in the body. Comparing results of diagnostic procedures done before, during, and after hormone therapy may help measure a patient's response to treatment.

Conditions Studied

Stage IV Breast Cancer AJCC v6 and v7 Estrogen Receptor Positive Primary or Recurrent Breast Carcinoma

Interventions

  • PROCEDURE Computed Tomography
  • PROCEDURE Positron Emission Tomography
  • DRUG F-18 16 Alpha-Fluoroestradiol
  • DRUG Fludeoxyglucose F-18

Study Locations (1)

Washington

  • Fred Hutch/University of Washington Cancer Consortium - Seattle

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2021-07-10
Est. Completion 2041-04-30
Phase Phase 2

Sponsor

University of Washington

1,048 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04692103

The ClinicalTrials.gov registry entry for NCT04692103 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 137-participant average among 14 other Stage IV Breast Cancer AJCC v6 and v7 trials with a reported enrollment target (99% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Stage IV Breast Cancer AJCC v6 and v7 appearing as the primary indexed condition, and to 4 interventions - of which Computed Tomography is the first listed.

NCT04692103 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT04692103 about?

NCT04692103 is a clinical study titled "Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy". This clinical trial studies use of F-18 16 alpha-fluoroestradiol (\[F-18\] FES) positron emission tomography (PET)/computed tomography (CT) in measuring tumor hormone receptor expression in patients undergoing endocrine-targeted therapy for newly diagnosed breast cancer or breast cancer that has com...

What is the current status of trial NCT04692103?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2021-07-10. Estimated completion is 2041-04-30.

What conditions does trial NCT04692103 study?

This clinical trial studies the following conditions: Stage IV Breast Cancer AJCC v6 and v7, Estrogen Receptor Positive, Primary or Recurrent Breast Carcinoma.

What interventions are being tested in trial NCT04692103?

The interventions under investigation include: Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), F-18 16 Alpha-Fluoroestradiol (DRUG), Fludeoxyglucose F-18 (DRUG).

Who is sponsoring clinical trial NCT04692103?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04692103 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage IV Breast Cancer AJCC v6 and v7

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Stage IV Breast Cancer AJCC v6 and v7

All registered trials for this condition

Estrogen Receptor Positive

All registered trials for this condition

Washington

All trials with a study site in Washington

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.